← Back to Search

CAR T-cell Therapy

Adoptive Cell Therapy for Cancer

Phase 1
Recruiting
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants who have received at least one dose of GSK adoptive cell therapy agent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 years
Awards & highlights

Study Summary

This trial will evaluate the long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy.

Who is the study for?
This trial is for people who have previously received GSK adoptive cell therapy as a treatment for tumors. They should be able to consent, have finished or withdrawn from a related GSK study, or completed treatment through managed access. Participants must follow local contraception guidelines and have taken at least one dose of the therapy.Check my eligibility
What is being tested?
The trial is monitoring the long-term safety of GSK's adoptive cell therapy in patients up to 15 years after their last infusion. It aims to track any late-emerging side effects and overall health outcomes following the treatment.See study design
What are the potential side effects?
Since this is a long-term follow-up study, it focuses on observing any delayed side effects that may arise from previous treatments with GSK adoptive cell therapy rather than introducing new interventions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have received at least one dose of a GSK cell therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with delayed adverse events (AEs) and serious adverse events (SAEs)
Secondary outcome measures
Number of deaths
Number of participants with Vesicular Stomatitis Virus G protein (VSV-G) Deoxyribonucleic acid (DNA) copies in peripheral blood samples
Hepatitis Viruses
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants receiving GSK adoptive cell therapyExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor
4,755 Previous Clinical Trials
8,070,566 Total Patients Enrolled
5 Trials studying Tumors
1,919 Patients Enrolled for Tumors
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,595 Previous Clinical Trials
6,143,680 Total Patients Enrolled
1 Trials studying Tumors
12 Patients Enrolled for Tumors

Media Library

Tumors Research Study Groups: Participants receiving GSK adoptive cell therapy
Tumors Clinical Trial 2023: GSK adoptive cell therapy Highlights & Side Effects. Trial Name: NCT03391778 — Phase 1
GSK adoptive cell therapy (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03391778 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has GSK's adoptive cell therapy attained regulatory clearance?

"This early-stage trial has minimal safety or efficacy data available, so GSK's adoptive cell therapy was assigned a score of 1."

Answered by AI

Is this research endeavor open to new participants?

"Data hosted on clinicaltrials.gov shows that this medical trial is now welcoming participants. This experiment was first put online on April 9th 2018, and has been modified as recently as November 21st 2022."

Answered by AI

What is the current cohort size of this experiment?

"Affirmative. Clinicaltrials.gov's records show that this clinical trial, initially posted on 4/9/2018, is actively enrolling subjects with up to 250 participants being admitted at 31 different sites."

Answered by AI

How extensively is this trial being conducted throughout the medical field?

"This clinical trial is being conducted across 31 medical centres, including New Haven, Philadelphia and Salt Lake City. To reduce any potential travel burden on participants it's recommended to choose the centre nearest you."

Answered by AI

Who else is applying?

What site did they apply to?
GSK Investigational Site
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
2018. "Adoptive Cell Therapy Long-term Follow-up (LTFU) Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03391778.
All > Cancer > Oncology
~142 spots leftby Apr 2032
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top